Search

Author/Creator Dobo, S.

1. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study. Issue 9 (17th June 2018)

Authors:
Riedl, M. A.; Aygören‐Pürsün, E.; Baker, J.; Farkas, H.; Anderson, J.; Bernstein, J. A.; Bouillet, L.; Busse, P.; Manning, M.; Magerl, M.; Gompels, M.; Huissoon, A. P.; Longhurst, H.; Lumry, W.; Ritchie, B.; Shapiro, R.; Soteres, D.; Banerji, A.; Cancian, M.; Johnston, D. T.
Journal:
Allergy
Issue:
Volume 73:Issue 9(2018)
Page Start:
1871
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. FRI0380 Long-term safety of BCX4208 added to allopurinol in the chronic management of GOUT: Results of a phase 2 24-week blinded safety extension and vaccine challenge study. (23rd January 2014)

Authors:
Hollister, A.S.; Dobo, S.; Maetzel, A.; Becker, M.A.; Terkeltaub, R.; Fitz-Patrick, D.; Smith, V.; Sheridan, W.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 71(2012)Supplement 3
Page Start:
442
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. P826: FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS. (23rd June 2022)

Authors:
Kulasekararaj, A.; Füreder, W.; McDonald, A.; Malherbe, J. L. R.; Gandhi, S.; Collins, D.; Cornpropst, M.; Dobo, S.; Farmer, M. K.; Kargl, D.; Sheridan, W.; Griffin, M.; Risitano, A.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
720
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗